Nature's Sunshine Products, Inc. logo

Nature's Sunshine Products, Inc.

NATR

NASDAQConsumer DefensivePackaged Foods

Previous close

$14.34

+$0.02 · +0.14%

Aug 21, 4:00 PM ET

NATR company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

81

Deep Value

Momentum

39

Weakening

Sentiment

76

Bullish

Risk resilience

63

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Nature's Sunshine Products, Inc. is a natural health and wellness enterprise that primarily manufactures and distributes a wide array of nutritional supplements and personal care products. The company's operational reach spans several continents, including Asia, Europe, North America, and Latin America. Its comprehensive nutritional offerings cater to general well-being, providing support for blood sugar regulation, bone density, cellular vitality, cognitive sharpness, joint mobility, mood balance, sexual wellness, sleep quality, athletic performance, and visual acuity. Additionally, it supplies specialized products for immune support, cardiovascular health, and digestive function, alongside solutions for weight management. In the personal care segment, their product line includes items such as essential oils and lotions, aloe vera gels, botanical shampoos, herbal skin treatments, dental care products like toothpaste, and skin cleansing formulations. These goods are sold under the company's proprietary Nature's Sunshine and Synergy WorldWide brands, primarily through an extensive network of independent sales consultants. Established in 1972, the organization is headquartered in Lehi, Utah.

Industry
Packaged Foods
Sector
Consumer Defensive
Headquarters
US
CEO
Kenneth G. Romanzi
Listed since
Jun 25, 2009
Employees
806

Market position

Day range

Current $14.34

52-week range

Current $14.34

Open
$14.335
Previous close
$14.32
Volume
249.78K
1.81× average
Average volume
138.15K
Average daily volume
Market cap
252.17M USD
Beta
0.89
Market reference 1
50-day average
$19.5626
-26.70% below average
200-day average
$22.4733
-36.19% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
14.06×
P/B (TTM)
1.51×
P/S (TTM)
0.51×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
73.16%
Operating margin
5.96%
Net margin
3.68%

Financial health

Debt / equity
0.13×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends81%52%22%-8%Gross margin, FY2021: 74.00%Gross margin, FY2022: 71.05%Gross margin, FY2023: 72.11%Gross margin, FY2024: 71.46%Gross margin, FY2025: 72.42%Operating margin, FY2021: 7.81%Operating margin, FY2022: 3.85%Operating margin, FY2023: 4.21%Operating margin, FY2024: 4.42%Operating margin, FY2025: 5.15%Net margin, FY2021: 6.50%Net margin, FY2022: -0.09%Net margin, FY2023: 3.39%Net margin, FY2024: 1.69%Net margin, FY2025: 4.07%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 74.00%. Gross margin FY2022 71.05%. Gross margin FY2023 72.11%. Gross margin FY2024 71.46%. Gross margin FY2025 72.42%. Operating margin FY2021 7.81%. Operating margin FY2022 3.85%. Operating margin FY2023 4.21%. Operating margin FY2024 4.42%. Operating margin FY2025 5.15%. Net margin FY2021 6.50%. Net margin FY2022 -0.09%. Net margin FY2023 3.39%. Net margin FY2024 1.69%. Net margin FY2025 4.07%.

Income trends

Revenue

480.14M USD+5.67%

Operating income

24.74M USD+23.13%

Net income

19.52M USD+153.65%
Income trends across reported periods528.2M USD335.98M USD143.77M USD−48.44M USDRevenue, FY2021: 444.08M USDRevenue, FY2022: 421.91M USDRevenue, FY2023: 445.32M USDRevenue, FY2024: 454.36M USDRevenue, FY2025: 480.14M USDOperating income, FY2021: 34.67M USDOperating income, FY2022: 16.26M USDOperating income, FY2023: 18.75M USDOperating income, FY2024: 20.1M USDOperating income, FY2025: 24.74M USDNet income, FY2021: 28.85M USDNet income, FY2022: −390K USDNet income, FY2023: 15.08M USDNet income, FY2024: 7.7M USDNet income, FY2025: 19.52M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 444.08M USD. Revenue FY2022 421.91M USD. Revenue FY2023 445.32M USD. Revenue FY2024 454.36M USD. Revenue FY2025 480.14M USD. Operating income FY2021 34.67M USD. Operating income FY2022 16.26M USD. Operating income FY2023 18.75M USD. Operating income FY2024 20.1M USD. Operating income FY2025 24.74M USD. Net income FY2021 28.85M USD. Net income FY2022 −390K USD. Net income FY2023 15.08M USD. Net income FY2024 7.7M USD. Net income FY2025 19.52M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue480.14M USD454.36M USD445.32M USD421.91M USD444.08M USD
Cost of goods sold132.42M USD129.68M USD124.19M USD122.15M USD115.47M USD
Gross profit347.72M USD324.69M USD321.13M USD299.76M USD328.62M USD
Research and development1.7M USD1.5M USD
Selling, general, and administrative322.98M USD304.59M USD302.38M USD283.5M USD293.95M USD
Operating expenses322.98M USD304.59M USD302.38M USD283.5M USD293.95M USD
Interest income645K USD177K USD552K USD123K USD466K USD
Interest expense98K USD146K USD69K USD249K USD250K USD
Depreciation and amortization13.84M USD14.22M USD11.82M USD15.68M USD11.16M USD
Operating income24.74M USD20.1M USD18.75M USD16.26M USD34.67M USD
Net income19.52M USD7.7M USD15.08M USD−390K USD28.85M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$31.00

116.18% upside
Past 12 months12-month forecastHigh $37.00Average $31.00Low $25.00

Rating distribution

4 ratings

Limited analyst sample: 4 ratings. Interpret the distribution with caution.

Strong buy00%
Buy250%
Hold250%
Sell00%
Strong sell00%

NATR news

NATR peers

ETFs holding NATR

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research NATR

research.disclaimer